What is the 13F Pro Quality Score for ONC?

13F Pro ranks BeOne Medicines Ltd. (ONC) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ONC's current score at https://13fpro.ai/company/ONC (free sign-up required for the full ranking).

Which hedge funds own the most ONC stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ONC include BAKER BROS. ADVISORS, PRIMECAP MANAGEMENT CO/CA/, Capital International Investors. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/ONC as soon as new 13F filings post.

Where does 13F Pro source ONC data?

All BeOne Medicines Ltd. fundamentals and ownership data come directly from SEC EDGAR. BeOne Medicines Ltd. files with the SEC under CIK 1651308. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ONC in?

BeOne Medicines Ltd. (ONC) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives ONC's revenue?

Per BeOne Medicines Ltd.'s latest 10-Q filed with the SEC on 2026-08-05, the biggest revenue drivers are: BRUKINSA (zanubrutinib) ($1,247.6M, +31.4% YoY); TEVIMBRA (tislelizumab) ($228.5M, +18.1% YoY); Amgen licensed products (XGEVA, BLINCYTO, KYPROLIS) ($157.3M, +24.5% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/ONC.

How often is ONC research updated on 13F Pro?

ONC's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

BeOne Medicines Ltd.(ONC)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqmega

Institutional-grade research for retail investors

SEC EDGAR: CIK 1651308 ONC stock profile & AI dashboard →

InternationalScored off the official board: an annual-only filer, so this data lags a domestic quarterly filer.

13F Pro Quality Score

74.9/100

Rank #104 of 2,962 stocksTOP 5%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why ONC Scores 75/100

exact factor attribution · 2026-09-11

ONC's composite is driven by revenue growth and scale, held back by shareholder dilution. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+8.4 pts

92th pct

Scale

+4.5 pts

80th pct

Free cash flow

+3.8 pts

75th pct

Earnings quality

+3.5 pts

86th pct

Profitability

+3.5 pts

73th pct

Capital efficiency

+3.2 pts

82th pct

Earnings growth

+0.7 pts

65th pct

Institutional flow

-0.9 pts

33th pct

Shareholder dilution

-1.7 pts

16th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

ONC Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for BeOne Medicines Ltd. (ONC), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ONC at 74.9/100 on a 32-signal composite quality model, placing it at rank #104 of 2,962 stocks — the top 5% of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), BeOne Medicines Ltd. reports quarterly revenue of $1.7B, net income of $237.0M, free cash flow of $435.3M. Top institutional holders of ONC by reported 13-F value include BAKER BROS. ADVISORS, PRIMECAP MANAGEMENT, Capital International Investors, based on the most recent SEC filings. ONC trades on the Nasdaq exchange and files with the SEC under CIK 1651308. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ONC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BeOne Medicines Ltd. directly from SEC EDGAR. BeOne Medicines Ltd.'s 13F Pro composite quality score has ranged between 67 and 75 since 2026, currently 74.9 — an improving long-term trajectory across 48 quarterly and live scoring snapshots.

What's Driving ONC's Business? Latest 10-Q Breakdown

✓ 27/27 datapoints verified

AI-extracted from BeOne Medicines Ltd.'s 10-Q filed 2026-08-05 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Q2 revenue surged 30% to $1.7B driven by BRUKINSA growth of 31%, achieving diluted EPS of $0.16 GAAP and $2.05 per ADS.

Biggest Revenue Drivers

BRUKINSA (zanubrutinib)$1,247.6M+31.4% YoY

Robust demand growth and strong market share gains in U.S., Europe, and Rest of World

TEVIMBRA (tislelizumab)$228.5M+18.1% YoY

Growth from anti-PD-1 antibody commercialization across major markets

Biggest Revenue Drivers

Total revenue: $1,705.1M+29.6% YoY

BRUKINSA (zanubrutinib)$1,247.6M+31.4% YoY

Robust demand growth and strong market share gains in U.S., Europe, and Rest of World

TEVIMBRA (tislelizumab)$228.5M+18.1% YoY

Growth from anti-PD-1 antibody commercialization across major markets

Amgen licensed products (XGEVA, BLINCYTO, KYPROLIS)$157.3M+24.5% YoY

Increased XGEVA sales volume in China under Amgen collaboration

Other revenue$25.3M+91.1% YoY

Royalty revenue from Amgen IMDELLTRA sales and Novartis broad markets agreement

Largest Expense Items

Research and development$612.3M+16.6% YoY

Increased investment in pipeline advancement including BTK CDAC, CDK4, and PRMT5 programs plus higher Amgen co-development costs

Selling, general and administrative$593.2M+10.3% YoY

Continued investment in global commercial expansion primarily in U.S. and Europe

Cost of sales - product$174.5M+6.0% YoY

Production productivity improvements and favorable product mix

Margins: Gross margin expanded to 89.6% for Q2 2026 from 87.4% YoY, driven by higher BRUKINSA proportion of sales mix and manufacturing efficiency gains. Operating margin improved significantly as revenue growth outpaced expense growth, with operating expenses growing only 13.4% while revenue grew 29.6%.

Watch Items from the Filing

Amgen royalty sale liability of $906.3M recorded; repayment depends on future IMDELLTRA royalties through at least 2041 with effective imputed interest rate of 11.0%.
Total debt obligations of $1,073.1M outstanding; $201.1M due within 12 months. Facilities Agreement requires compliance with financial covenants including minimum cash interest coverage ratio of 5.00x and maximum net leverage ratio of 2.50x.
BRUKINSA faces potential generic competition; Zydus filed ANDA in February 2026 with Paragraph IV certifications challenging patents. Company initiated patent infringement litigation but generic composition-of-matter patent remains intact until 2034.
AbbVie litigation alleging misappropriation of trade secrets for BTK degrader program BGB-16673 remains ongoing; motion to dismiss denied May 2026; no trial date scheduled.
Operating cash flow of $664.2M for first six months 2026 versus $307.7M YoY, representing positive operating cash generation trajectory and reduced reliance on external financing.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$1.7B

Net Income

Q2 2026

$237.0M

Free Cash Flow

Q2 2026

$435.3M

ROIC

Q2 2026

20.6%

D/E Ratio

Q2 2026

0.22

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+40.2% YoY

$5.34BFY 2025

FY22 $1.42BFY23 $2.46BFY24 $3.81BFY25 $5.34B

Net Income

+144.5% YoY

$286.9MFY 2025

FY22 $-2.00BFY23 $-881.7MFY24 $-644.8MFY25 $286.9M

Operating Income

+178.7% YoY

$447.1MFY 2025

FY22 $-1.79BFY23 $-1.21BFY24 $-568.2MFY25 $447.1M

EPS (Diluted)

+140.4% YoY

$0.19FY 2025

FY22 $-1.49FY23 $-0.65FY24 $-0.47FY25 $0.19

Total Assets

+38.3% YoY

$8.19BFY 2025

FY22 $6.38BFY23 $5.81BFY24 $5.92BFY25 $8.19B

Total Debt

-45.0% YoY

$1.03BFY 2025

FY22 $538.1MFY23 $2.09BFY24 $1.87BFY25 $1.03B

Op. Cash Flow

+901.8% YoY

$1.13BFY 2025

FY22 $-1.50BFY23 $-1.16BFY24 $-140.6MFY25 $1.13B

Free Cash Flow

+248.7% YoY

$941.7MFY 2025

FY22 $-1.82BFY23 $-1.72BFY24 $-633.3MFY25 $941.7M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$5.34B +40.2%	$3.81B +55.0%	$2.46B +73.7%	$1.42B +20.4%	$1.18B +280.8%	$308.9M
Net Income	$286.9M +144.5%	$-644.8M +26.9%	$-881.7M +56.0%	$-2.00B -37.5%	$-1.46B +10.3%	$-1.62B
Operating Income	$447.1M +178.7%	$-568.2M +53.0%	$-1.21B +32.5%	$-1.79B -24.4%	$-1.44B +13.2%	$-1.66B
EPS (Diluted)	$0.19 +140.4%	$-0.47 +27.7%	$-0.65 +56.4%	$-1.49 -23.1%	$-1.21 +19.3%	$-1.50
Total Assets	$8.19B +38.3%	$5.92B +2.0%	$5.81B -9.0%	$6.38B -25.3%	$8.54B +52.4%	$5.60B
Total Debt	$1.03B -45.0%	$1.87B -10.6%	$2.09B +288.6%	$538.1M -86.6%	$4.01B +370.1%	$853.7M
Operating Cash Flow	$1.13B +901.8%	$-140.6M +87.8%	$-1.16B +22.7%	$-1.50B -15.2%	$-1.30B -1.2%	$-1.28B
Free Cash Flow	$941.7M +248.7%	$-633.3M +63.2%	$-1.72B +5.6%	$-1.82B -16.7%	$-1.56B -11.5%	$-1.40B

Get alerted when ONC's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for BeOne Medicines Ltd. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ONC

BAKER BROS. ADVISORS LP
$2.5B8,801,567 sh
PRIMECAP MANAGEMENT CO/CA/
$1.4B5,007,931 sh
Capital International Investors
$1.2B4,210,221 sh
FMR LLC
$706.3M2,478,527 sh
Capital World Investors
$641.1M2,249,582 sh
CITADEL ADVISORS LLC
$406.2M1,425,517 sh
Temasek Holdings (Private) Ltd
$241.0M845,729 sh
PRICE T ROWE ASSOCIATES INC /MD/
$216.2M758,752 sh
BlackRock, Inc.
$197.9M694,618 sh
MILLENNIUM MANAGEMENT LLC
$154.8M543,323 sh

Fund	Value	Shares
BAKER BROS. ADVISORS LP	$2.5B	8,801,567
PRIMECAP MANAGEMENT CO/CA/	$1.4B	5,007,931
Capital International Investors	$1.2B	4,210,221
FMR LLC	$706.3M	2,478,527
Capital World Investors	$641.1M	2,249,582
CITADEL ADVISORS LLC	$406.2M	1,425,517
Temasek Holdings (Private) Ltd	$241.0M	845,729
PRICE T ROWE ASSOCIATES INC /MD/	$216.2M	758,752
BlackRock, Inc.	$197.9M	694,618
MILLENNIUM MANAGEMENT LLC	$154.8M	543,323

Companies Similar to ONC

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

ALNY

ALNYLAM PHARMACEUTICALS, INC.

AI score

Similar quality profile · 18 shared holders

Capital World Investors Candriam S.C.A.Life Cycle Investment Partners Ltd

HALO

HALOZYME THERAPEUTICS, INC.

AI score

Similar quality profile · 5 shared holders

M&G Plc SEB Asset Management AB Capital World Investors

PODD

INSULET CORP

AI score

Similar quality profile · 12 shared holders

Artisan Partners Limited Partnership Capital World Investors Candriam S.C.A.

CAI

Caris Life Sciences, Inc.

AI score

Similar quality profile · 9 shared holders

Capital World Investors China Universal Asset Management Co., Ltd.EDMOND DE ROTHSCHILD HOLDING S.A.

UTHR

UNITED THERAPEUTICS Corp

AI score

Similar quality profile · 10 shared holders

Candriam S.C.A.Patient Square Capital LP Life Cycle Investment Partners Ltd

ARQT

Arcutis Biotherapeutics, Inc.

AI score

Similar quality profile · 10 shared holders

JENNISON ASSOCIATES LLC Candriam S.C.A.DRIEHAUS CAPITAL MANAGEMENT LLC

HRMY

Harmony Biosciences Holdings, Inc.

AI score

Similar quality profile · 9 shared holders

Virtus Investment Advisers, LLC Nan Fung Group Holdings Ltd SEB Asset Management AB

ANIP

ANI PHARMACEUTICALS INC

AI score

Similar quality profile · 6 shared holders

DRIEHAUS CAPITAL MANAGEMENT LLC SEB Asset Management AB China Universal Asset Management Co., Ltd.

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ONC on your watchlist

Track score changes the day BeOne Medicines Ltd. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ONC a good stock to buy?

13F Pro's AI-powered analysis of BeOne Medicines Ltd. (ONC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ONC are available on the ONC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ONC is classified as a mega company.

Which hedge funds own ONC?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ONC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of BeOne Medicines Ltd.'s investment landscape.